HepatologyGilead
Gilead Sciences Receives FDA Approval for Livdelzi in Primary Biliary Cholangitis
BMI
Biotechnology Media Insights
Editorial Team · March 28, 2025
Gilead Sciences announces FDA approval of Livdelzi (seladelpar) for adults with primary biliary cholangitis who have inadequate response to ursodeoxycholic acid.
Gilead Sciences today announced that the FDA has approved Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) or as monotherapy in patients unable to tolerate UDCA.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.